Shp2 a Non-Receptor Tyrosine Phosphatase Regulates Nephrin Phosphorylation and Po

Shp2 非受体酪氨酸磷酸酶调节去氧肾上腺素磷酸化和 Po

基本信息

  • 批准号:
    8785120
  • 负责人:
  • 金额:
    $ 33.82万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-01-01 至 2018-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Proteinuric kidney diseases, including diabetic nephropathy are responsible for majority of the patients that develop end stage renal disease. Proteinuria is not only important for progression of kidney disease but is also an important cardiovascular risk factor. Podocytes have been the main focus of investigations in glomerular diseases that present with proteinuria. Recent studies suggest that podocyte foot process effacement is a form of podocyte mobility that is a result of increase in lamellipodia formation. Nephrin ability to regulate podocyte actin dynamics, lamellipodia formation and focal adhesion dynamics in a phosphorylation dependent manner suggests its role in foot process effacement. Hypothesis: Hypothesis: Inhibition of signaling events that increase podocyte mobility or prevent lamellipodia formation will prevent podocyte foot process spreading and loss following injury. Rationale: Increase in Nephrin phosphorylation has been observed following podocyte injury. Our preliminary data suggests that Src kinase dependent Nephrin phosphorylation is regulated by non- receptor tyrosine phosphatase shp2. Furthermore, inhibition of Shp2 prevents podocyte foot process effacement in protamine sulfate model of podocyte injury. Specific Aims: We will test our hypothesis by pursuing the following two specific aims. 1) Define regulation of Nephrin phosphorylation by Shp2. Using biochemical and cell biology techniques we will expand on our preliminary observations and define the protein-protein interaction and functional consequences of Shp2 dependent Nephrin phosphorylation. 2) Characterize signaling mechanism by which integrin activation regulates Nephrin phosphorylation. We will examine the molecular mechanism that result in Nephrin phosphorylation. Our preliminary experiments suggest that Nephrin phosphorylation occurs as a result of integrin activation. 2) Determine the role of Shp2 and Nephrin phosphorylation on podocyte homeostasis in vivo. We will generate an inducible and a non-inducible podocyte specific conditional shp2 knockout mouse. This mouse will enable us to study the role of shp2 during development and following injury. We will also be able to examine the benefit of preventing foot process effacement in podocyte injury models like protamine sulfate specifically in regards to podocyte loss and proteinuria. Using these mice we will also be able to test other models of podocyte injury.
描述(由申请方提供):蛋白尿性肾病,包括糖尿病肾病,是大多数发展为终末期肾病的患者的原因。蛋白尿不仅是肾脏疾病进展的重要因素,也是重要的心血管危险因素。足细胞一直是以蛋白尿为表现的肾小球疾病研究的主要焦点。最近的研究表明,足细胞足突消失是足细胞运动的一种形式,是板状伪足形成增加的结果。Nephrin以磷酸化依赖的方式调节足细胞肌动蛋白动力学、板状伪足形成和粘着斑动力学的能力表明其在足突消失中的作用。假设:假设:抑制增加足细胞移动性或防止板状伪足形成的信号传导事件将防止足细胞足突扩展和损伤后的损失。原理:足细胞损伤后观察到Nephrin磷酸化增加。我们的初步数据表明,Src激酶依赖性Nephrin磷酸化受非受体酪氨酸磷酸酶shp 2调节。此外,在足细胞损伤的硫酸鱼精蛋白模型中,抑制Shp 2防止足细胞足突消失。具体目标:我们将通过追求以下两个具体目标来测试我们的假设。1)定义Shp 2对Nephrin磷酸化的调节。利用生物化学和细胞生物学技术,我们将扩大我们的初步观察,并确定蛋白质-蛋白质相互作用和功能的Shp 2依赖性Nephrin磷酸化的后果。2)表征整合素活化调节肾蛋白磷酸化的信号传导机制。我们将研究导致Nephrin磷酸化的分子机制。我们的初步实验表明,Nephrin磷酸化发生的结果整合素激活。2)确定Shp 2和Nephrin磷酸化对体内足细胞稳态的作用。我们将产生诱导型和非诱导型足细胞特异性条件shp 2敲除小鼠。这只小鼠将使我们能够研究shp 2在发育过程中和损伤后的作用。我们还将能够检查在足细胞损伤模型中预防足突消失的益处,如硫酸鱼精蛋白,特别是在足细胞损失和蛋白尿方面。使用这些小鼠,我们也将能够测试足细胞损伤的其他模型。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PUNEET GARG其他文献

PUNEET GARG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PUNEET GARG', 18)}}的其他基金

Shp2 a Non-Receptor Tyrosine Phosphatase Regulates Nephrin Phosphorylation and Po
Shp2 非受体酪氨酸磷酸酶调节去氧肾上腺素磷酸化和 Po
  • 批准号:
    9199082
  • 财政年份:
    2014
  • 资助金额:
    $ 33.82万
  • 项目类别:
Shp2 a Non-Receptor Tyrosine Phosphatase Regulates Nephrin Phosphorylation and Po
Shp2 非受体酪氨酸磷酸酶调节去氧肾上腺素磷酸化和 Po
  • 批准号:
    8995200
  • 财政年份:
    2014
  • 资助金额:
    $ 33.82万
  • 项目类别:
Shp2 a Non-Receptor Tyrosine Phosphatase Regulates Nephrin Phosphorylation and Po
Shp2 非受体酪氨酸磷酸酶调节去氧肾上腺素磷酸化和 Po
  • 批准号:
    8629068
  • 财政年份:
    2014
  • 资助金额:
    $ 33.82万
  • 项目类别:
Role of Endocytosis and Vesicular Trafficking in Podocyte Health and Filter Integ
内吞作用和囊泡运输在足细胞健康和过滤器完整性中的作用
  • 批准号:
    8355212
  • 财政年份:
    2012
  • 资助金额:
    $ 33.82万
  • 项目类别:
Regulation of Podocyte Actin Cytoskeleton
足细胞肌动蛋白细胞骨架的调节
  • 批准号:
    7994909
  • 财政年份:
    2010
  • 资助金额:
    $ 33.82万
  • 项目类别:
Regulation of Podocyte Actin Cytoskeleton
足细胞肌动蛋白细胞骨架的调节
  • 批准号:
    7509978
  • 财政年份:
    2008
  • 资助金额:
    $ 33.82万
  • 项目类别:
Regulation of Podocyte Actin Cytoskeleton
足细胞肌动蛋白细胞骨架的调节
  • 批准号:
    7658745
  • 财政年份:
    2008
  • 资助金额:
    $ 33.82万
  • 项目类别:
Regulation of Podocyte Actin Cytoskeleton
足细胞肌动蛋白细胞骨架的调节
  • 批准号:
    7892559
  • 财政年份:
    2008
  • 资助金额:
    $ 33.82万
  • 项目类别:
Regulation of Podocyte Actin Cytoskeleton
足细胞肌动蛋白细胞骨架的调节
  • 批准号:
    8110555
  • 财政年份:
    2008
  • 资助金额:
    $ 33.82万
  • 项目类别:
Regulation of Podocyte Actin Cytoskeleton
足细胞肌动蛋白细胞骨架的调节
  • 批准号:
    8290587
  • 财政年份:
    2008
  • 资助金额:
    $ 33.82万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 33.82万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 33.82万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 33.82万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 33.82万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 33.82万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 33.82万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 33.82万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 33.82万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 33.82万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 33.82万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了